RxDoctor Payments Data

Mark Williams

Psychiatric/Mental Health · Mesa, AZNPI 1023786225

Payments from drug & device makers

$2,544in general payments, 2019–2025

Across 112 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$619
  • Teva Pharmaceuticals USA, Inc.$337
  • AbbVie$326
  • Johnson & Johnson$296
  • Otsuka America Pharmaceutical, Inc.$232
  • Lundbeck LLC$118
  • plus $616 from 11 others

What the payments were for

  • Food & beverage$2,544100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,544 in reported general payments places this provider in the 85th percentile of 1,230 psychiatric/mental health providers in Arizona.

See all psychiatric/mental health providers in Arizona

Medicare billing

Part B allowed, 2024
$7,773
Medicare patients
19
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl15$38,888
AdderallDextroamphetamine/Amphetamine22$10,333
BelsomraSuvorexant23$10,301
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl29$5,521
TrintellixVortioxetine Hydrobromide11$5,236
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine48$3,332
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine62$1,999
Quetiapine Fumarate92$1,741
Duloxetine Hcl57$1,578
Lamotrigine82$1,419
Aripiprazole64$1,352
Oxcarbazepine24$1,185
Clonazepam121$935
Risperidone28$882
Gabapentin46$682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$326$38,88815 claims
Takeda Pharmaceuticals U.S.A., Inc.Adderall, Trintellix$33$15,56933 claims
Almatica Pharma LLCSertraline Hcl$21$43638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,230 psychiatric/mental health providers in Arizona.

Other psychiatric/mental health in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →